Last reviewed · How we verify
LV5FU2
LV5FU2 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis to kill rapidly dividing cancer cells.
LV5FU2 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Advanced gastric cancer.
At a glance
| Generic name | LV5FU2 |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Drug class | Antimetabolite chemotherapy combination |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
LV5FU2 combines leucovorin (folinic acid), 5-fluorouracil (5-FU), and additional agents to enhance antimetabolite activity. Leucovorin potentiates 5-FU by stabilizing its binding to thymidylate synthase, thereby increasing the inhibition of DNA and RNA synthesis in cancer cells. This combination is designed to improve efficacy in colorectal and other solid tumors.
Approved indications
- Metastatic colorectal cancer
- Advanced gastric cancer
Common side effects
- Neutropenia
- Diarrhea
- Mucositis
- Nausea and vomiting
- Anemia
Key clinical trials
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer (PHASE2)
- MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents (NA)
- 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab (PHASE2)
- QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (PHASE3)
- Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (PHASE3)
- PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment (PHASE2)
- FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (PHASE2)
- DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LV5FU2 CI brief — competitive landscape report
- LV5FU2 updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Besancon portfolio CI